Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in We...
January 28 2020 - 4:02PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced the presentation of 24-week data from the
second cohort of patients (n=6; 2 x 1011 vg/eye) as well as an
update from the first cohort of patients (n=6; 6 x 1011 vg/eye) in
the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene
therapy in wet AMD at the Angiogenesis, Exudation, and Degeneration
2020 Meeting.
Oral Presentation Details: |
Event: |
Angiogenesis, Exudation, and Degeneration 2020 Meeting |
Title: |
Phase1 Study
of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD
(OPTIC Trial) |
Session: |
Session VII:
Treatments for Neovascularization in AMD and ROP |
Date: |
February 8,
2020 |
Time: |
2:28 pm
EST |
Location: |
Mandarin
Oriental Hotel, Miami, FL |
Speaker: |
David S.
Boyer, M.D., senior partner, Retina-Vitreous Associates Medical
Group and adjunct clinical professor of ophthalmology with the
University of Southern California/Keck School of Medicine in
Los Angeles, California. |
Adverum plans to issue a press release relating to the
presentation and post the presentation on Adverum’s website at
www.adverum.com in the Investors section under the Events and
Presentations page at the beginning of the data presentation at
Angiogenesis.
KOL Event Details:In addition, Adverum will
host an event with expert retinal specialists to discuss the OPTIC
data presented at Angiogenesis and the potential opportunity for
ADVM-022. The discussion will be held on Sunday, February 9, 2020
beginning at 10:00 am EST. The event will be webcast live from
Adverum’s website at www.adverum.com in the Investors section under
the Events and Presentations page. A replay of the webcast will be
archived and available for replay following the event.
About Adverum BiotechnologiesAdverum
Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy
company targeting unmet medical needs in serious ocular and rare
diseases. Adverum is evaluating its novel gene therapy candidate,
ADVM-022, as a one-time, intravitreal injection for the treatment
of its lead indication, wet age-related macular degeneration. For
more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors:
Myesha Lacy
Adverum Biotechnologies, Inc.
mlacy@adverum.com
1-650-649-1257
Media:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
1-646-876-5196
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024